Principal Financial Group Inc Nuvation Bio Inc. Transaction History

Principal Financial Group Inc

  • $1.66 Trillion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024
SELL
$2.3 - $3.83 $30,930 - $51,505
-13,448 Reduced 51.82%
12,502 $28,000
Q2 2024

Jul 29, 2024
BUY
$2.58 - $3.69 $24,775 - $35,435
9,603 Added 58.74%
25,950 $75,000
Q1 2024

Apr 29, 2024
SELL
$1.46 - $3.97 $1,749 - $4,756
-1,198 Reduced 6.83%
16,347 $59,000
Q4 2023

Feb 07, 2024
SELL
$0.96 - $1.53 $2,789 - $4,446
-2,906 Reduced 14.21%
17,545 $26,000
Q3 2023

Nov 02, 2023
BUY
$1.26 - $2.1 $6,278 - $10,464
4,983 Added 32.21%
20,451 $27,000
Q2 2023

Aug 07, 2023
SELL
$1.56 - $1.84 $51,862 - $61,170
-33,245 Reduced 68.25%
15,468 $27,000
Q1 2023

May 09, 2023
BUY
$1.6 - $2.48 $5,600 - $8,680
3,500 Added 7.74%
48,713 $80,000
Q4 2022

Feb 09, 2023
BUY
$1.68 - $2.5 $13,937 - $20,740
8,296 Added 22.47%
45,213 $86,000
Q3 2022

Nov 09, 2022
BUY
$0.29 - $4.04 $1,854 - $25,835
6,395 Added 20.95%
36,917 $82,000
Q2 2022

Aug 10, 2022
SELL
$3.24 - $5.85 $66,539 - $120,141
-20,537 Reduced 40.22%
30,522 $99,000
Q1 2022

May 09, 2022
BUY
$4.6 - $8.83 $832 - $1,598
181 Added 0.36%
51,059 $268,000
Q4 2021

Feb 09, 2022
BUY
$7.75 - $10.05 $296,112 - $383,990
38,208 Added 301.56%
50,878 $433,000
Q3 2021

Nov 09, 2021
BUY
$7.78 - $10.0 $98,572 - $126,700
12,670 New
12,670 $126,000

Others Institutions Holding NUVB

# of Institutions
158
Shares Held
157M
Call Options Held
3.2K
Put Options Held
98.7K
View Full List

About Nuvation Bio Inc.

NUVB Quotes by TradingView
  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $613M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email